Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 14/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252346 | 0.99 | PARP1 (0.59) | PARP1KDM4ETSHRALDH1A1LMNA | |
| SCHEMBL1251316 | 0.97 | PARP1 (0.63) | PARP1KDM4ETSHRALDH1A1LMNA | |
| SCHEMBL1249992 | 0.95 | PARP1 (0.56) | PARP1KDM4ETSHR | |
| SCHEMBL1251260 | 0.93 | PARP1 (0.62) | PARP1KDM4ETSHRTP53HSD17B10 | |
| SCHEMBL1251344 | 0.87 | PARP1 (0.52) | PARP1KDM4ETSHRALDH1A1TP53 | |
| Hydrochloric Acid SCHEMBL1251976 | 0.87 | PARP1 (0.60) | PARP1ALDH1A1 | |
| SCHEMBL1252549 | 0.87 | PARP1 (0.61) | PARP1ALDH1A1 | |
| SCHEMBL1251222 | 0.84 | PARP1 (0.53) | PARP1KDM4ETSHRALDH1A1LMNA | |
| SCHEMBL1252198 | 0.82 | PARP1 (0.60) | PARP1 | |
| Hydrochloric Acid SCHEMBL1251196 | 0.82 | PARP1 (0.58) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1477175-B1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-04-27 | — | — | EP | claimed |
| EP-2281818-A1 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-02-09 | — | — | EP | claimed |
| US-20090226412-A1 | AGENT FOR REDUCTION OF BLEEDING IN CEREBROVASCULAR DISORDER | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-09-10 | — | — | US | claimed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | claimed |
| EP-1908481-A1 | AGENT FOR REDUCTION OF BLEEDING IN CEREBROVASCULAR DISORDER | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-09 | — | — | EP | claimed |
| EP-1477175-B1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-04-27 | — | — | EP | disclosed |
| EP-2281818-A1 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20090226412-A1 | AGENT FOR REDUCTION OF BLEEDING IN CEREBROVASCULAR DISORDER | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. | 2008-10-23 | — | — | US | disclosed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| EP-1908481-A1 | AGENT FOR REDUCTION OF BLEEDING IN CEREBROVASCULAR DISORDER | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-09 | — | — | EP | disclosed |
| US-20050085476-A1 | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1477175-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226412-A1 | AGENT FOR REDUCTION OF BLEEDING IN CEREBROVASCULAR DISORDER | PARP1, PARP3, PARP2 | PARP1 1/4885KDM4E 1744/4885TSHR 4591/4885 |
| US-20050085476-A1 | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient | MUSK, RNASE1, DPYD | PARP1 4/4885KDM4E 3589/4885TSHR 4565/4885 |
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | MUSK, RNASE1, DPYD | PARP1 4/4885KDM4E 3575/4885TSHR 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.